KR20250086779A - 치환 피페라진 유도체의 결정 및 이의 제조 방법 - Google Patents

치환 피페라진 유도체의 결정 및 이의 제조 방법 Download PDF

Info

Publication number
KR20250086779A
KR20250086779A KR1020257016149A KR20257016149A KR20250086779A KR 20250086779 A KR20250086779 A KR 20250086779A KR 1020257016149 A KR1020257016149 A KR 1020257016149A KR 20257016149 A KR20257016149 A KR 20257016149A KR 20250086779 A KR20250086779 A KR 20250086779A
Authority
KR
South Korea
Prior art keywords
crystalline form
ray powder
powder diffraction
solvent
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257016149A
Other languages
English (en)
Korean (ko)
Inventor
짜오쥔 리우
홍쭈 추
위친 쭈
신 차오
용강 웨이
이 쑨
Original Assignee
캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. filed Critical 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디.
Publication of KR20250086779A publication Critical patent/KR20250086779A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020257016149A 2022-11-14 2023-11-14 치환 피페라진 유도체의 결정 및 이의 제조 방법 Pending KR20250086779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211417721 2022-11-14
CN202211417721.3 2022-11-14
PCT/CN2023/131627 WO2024104354A1 (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Publications (1)

Publication Number Publication Date
KR20250086779A true KR20250086779A (ko) 2025-06-13

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257016149A Pending KR20250086779A (ko) 2022-11-14 2023-11-14 치환 피페라진 유도체의 결정 및 이의 제조 방법

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도

Also Published As

Publication number Publication date
CN118027039A (zh) 2024-05-14
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
MX2025005591A (es) 2025-06-02
TWI879228B (zh) 2025-04-01
AU2023381502A1 (en) 2025-05-15
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
JP2025536416A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
JP6131384B2 (ja) 重水素化ジアミノピリミジン化合物およびこの化合物を含む薬物組成物
KR20240069725A (ko) 피리딘 유도체 및 이의 용도
US20250270223A1 (en) Crystal of substituted piperazine derivative and preparation method therefor
EP3632903B1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
EP3741752A1 (en) Tam family kinase /and csf1r kinase inhibitor and use thereof
CN107151249B (zh) 作为flt3抑制剂的蝶啶酮衍生物及应用
KR20120120271A (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물
CN114853672B (zh) 作为CDKs抑制剂的他克林衍生物及其应用
WO2018192536A1 (zh) 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
WO2020224626A1 (zh) 用作激酶抑制剂的化合物及其应用
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
EP3590941A1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
JP2022554385A (ja) Ｗｄｒ５阻害剤及び調節剤
KR20130005263A (ko) 치환된 나프탈레닐-피리미딘 화합물
KR20220020951A (ko) Cdk 키나제 억제제
KR102526281B1 (ko) 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도
CN118632843A (zh) 一种吡啶类衍生物及其用途
CN108299420B (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
CN117043163A (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
WO2024235289A1 (zh) 用于egfr蛋白降解的化合物及其用途
CN113880804A (zh) 新型苯并咪唑化合物
JP2954647B2 (ja) ヘキシトール誘導体
TWI525091B (zh) 吡咯並喹啉基－吡咯啶－２，５－二酮組成物類及製備和使用彼等之方法
CN117157284A (zh) Ctla-4小分子降解剂及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250516

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application